Gilead Sciences (NASDAQ:GILD) saw its share price trade relatively negative in the recent trading session. The share price was last updated to $82.66 with a loss of -0.85 points or -1.02%. The net money flow was $121.29 million and the up/down ratio was 2.78. Approximately $189.38 million was the inflow in upticks and $68.09 million was the outflow in downticks. On a weekly measure, the shares have seen a price change of -2.12%.The shares witnessed a block transaction with a net money flow of $117.52 million. The total money in uptick was $119.73 million and in downtick was $2.21 million with the up/down ratio reaching 54.26.
Gilead Sciences Inc. has dropped 1.58% in the last five trading days, however, the shares have posted positive gains of 0.28% in the last 4 weeks. Gilead Sciences Inc. has dropped 7.93% during the last 3-month period . Year-to-Date the stock performance stands at -17.47%.
Currently the company Insiders own 1.4% of Gilead Sciences shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.2% . Institutional Investors own 81.8% of Gilead Sciences shares. During last six month period, the net percent change held by insiders has seen a change of -9.29%. . On the companys insider trading activities,The director officer (President and CEO) of Gilead Sciences Inc, Milligan John F sold 112,000 shares at $86.92 on June 6, 2016. The Insider selling transaction had a total value worth of $9,735,040. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Gilead Sciences (NASDAQ:GILD) witnessed a decline in the market cap on Friday as its shares dropped 1.03% or 0.86 points. After the session commenced at $83.68, the stock reached the higher end at $84.17 while it hit a low of $82.53. With the volume soaring to 15,951,268 shares, the last trade was called at $82.65. The company has a 52-week high of $123.37. The company has a market cap of $110,075 million and there are 1,331,821,510 shares in outstanding. The 52-week low of the share price is $81.28.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.